Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
RESEARCH TOOLSreports
Holding EYPT?
Track your performance easily
EYPT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.67 - $30.99
Previous Close$8.91
Volume454.33K
Average Volume (3M)713.11K
Market Cap
$497.72M
Enterprise Value$218.76M
Total Cash (Recent Filing)$280.25M
Total Debt (Recent Filing)$22.16M
Price to Earnings (P/E)―
Beta2.36
Next Earnings
Oct 30, 2024EPS Estimate
-$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.80
Shares Outstanding53,518,210
10 Day Avg. Volume615,910
30 Day Avg. Volume713,106
Standard Deviation0.44
R-Squared0.04
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)1.91
Price to Sales (P/S)9.39
Price to Cash Flow (P/CF)-3.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.25
Enterprise Value/Gross Profit5.29
Enterprise Value/Ebitda-2.48
Forecast
1Y Price Target
$38.33Price Target Upside312.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EyePoint Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Market PotentialThe market for wet AMD drugs is projected to exceed $9B in the U.S./EU by 2030.
Product DifferentiationDURAVYU is differentiated from the current standard of care treatments because it incorporates vorolanib, a tyrosine kinase inhibitor, administered via an implant that releases the drug steadily over the course of around nine months.
Regulatory PathwayEyePoint held an end-of-Phase-2 meeting with the FDA in late April, where it got confirmation from the FDA on its proposed Phase 3 trial design for Duravyu in wet AMD.
Bears Say
Clinical DataMaintain low expectations for the 12-month data in the Phase 2 PAVIA trial in NPDR.
Clinical TrialsFollowing disappointing results for Duravyu in the Phase 2 PAVIA study in diabetic retinopathy (note) and discontinuation of further development in DR, the Phase 2 VERONA trial in diabetic macular edema (DME) comparing Duravyu to one dose of Eylea is fully enrolled.
Regulatory UncertaintyEYPT shares are being weighed down by the lack of a more robust update on the outcome of its April 23 Type C meeting with FDA.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
EYPT FAQ
What was EyePoint Pharmaceuticals Inc’s price range in the past 12 months?
EyePoint Pharmaceuticals Inc lowest stock price was $5.67 and its highest was $30.99 in the past 12 months.
What is EyePoint Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is EyePoint Pharmaceuticals Inc’s upcoming earnings report date?
EyePoint Pharmaceuticals Inc’s upcoming earnings report date is Oct 30, 2024 which is in 41 days.
How were EyePoint Pharmaceuticals Inc’s earnings last quarter?
EyePoint Pharmaceuticals Inc released its earnings results on Aug 07, 2024. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of -$0.505 by -$0.075.
Is EyePoint Pharmaceuticals Inc overvalued?
According to Wall Street analysts EyePoint Pharmaceuticals Inc’s price is currently Undervalued.
Does EyePoint Pharmaceuticals Inc pay dividends?
EyePoint Pharmaceuticals Inc does not currently pay dividends.
What is EyePoint Pharmaceuticals Inc’s EPS estimate?
EyePoint Pharmaceuticals Inc’s EPS estimate is -$0.56.
How many shares outstanding does EyePoint Pharmaceuticals Inc have?
EyePoint Pharmaceuticals Inc has 53,518,210 shares outstanding.
What happened to EyePoint Pharmaceuticals Inc’s price movement after its last earnings report?
EyePoint Pharmaceuticals Inc reported an EPS of -$0.58 in its last earnings report, missing expectations of -$0.505. Following the earnings report the stock price went down -4.102%.
Which hedge fund is a major shareholder of EyePoint Pharmaceuticals Inc?
Among the largest hedge funds holding EyePoint Pharmaceuticals Inc’s share is Deerfield Management Company, LP. It holds EyePoint Pharmaceuticals Inc’s shares valued at 8M.
---
EyePoint Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.33 (312.15% Upside)
$38.33 (312.15% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $67.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.76%
12-Months-Change
Fundamentals
Return on Equity
-60.81%
Trailing 12-Months
Asset Growth
84.59%
Trailing 12-Months
Company Description
EyePoint Pharmaceuticals Inc
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
---
EYPT Earnings Call
Q4 2024
0:00 / 0:00
---
EYPT Stock 12 Month Forecast
Average Price Target
$38.33
▲(312.15% Upside)
Technical Analysis
Best Analysts Covering EYPT
1 Year
1 Year Success Rate
6/11 ratings generated profit
1 Year Average Return
+18.31%
reiterated a buy rating last month
Copying Colleen M. Kusy's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +18.31% per trade.
---